Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2004-05-12

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/JM0498699PMID 15163209
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• In vitro and in vivo models for evaluation of GDEPT: quantifying bystander killing in cell cultures and tumors.

  2004cited by this paper
• 2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT

  2004cited by this paper
• Inhibition of myc-dependent breast tumor formation in transgenic mice

  2004cited by this paper
• Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2,4-dinitrobenzamide-5-aziridine CB 1954 and the corresponding nitrogen mustard SN 23862: distinct mechanisms of bioreductive activation.

  2003cited by this paper
• Studies on the nitroreductase prodrug-activating system. Crystal structures of complexes with the inhibitor dicoumarol and dinitrobenzamide prodrugs and of the enzyme active form.

  2003cited by this paper
• Selective ablation of olfactory receptor neurons without functional impairment of vomeronasal receptor neurons in OMP‐ntr transgenic mice

  2002cited by this paper
• Inducible ablation of adipocytes in adult transgenic mice expressing the E. coli nitroreductase gene.

  2002cited by this paper
• Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures.

  2002cited by this paper
• Gene directed enzyme/prodrug therapy of cancer: Historical appraisal and future prospectives

  2001cited by this paper
• Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954.

  2001cited by this paper
• Conditional ablation of neurones in transgenic mice.

  2001cited by this paper
• The structure of Escherichia coli nitroreductase complexed with nicotinic acid: three crystal forms at 1.7 A, 1.8 A and 2.4 A resolution.

  2001cited by this paper
• Aerobic nitroreduction by flavoproteins: enzyme structure, mechanisms and role in cancer chemotherapy.

  2001cited by this paper
• Inducible ablation of astrocytes shows that these cells are required for neuronal survival in the adult brain

  2001cited by this paper
• Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954

  2000cited by this paper
• Crystal structure of FMN-dependent nitroreductase from Escherichia coli B: a prodrug-activating enzyme.

  2000cited by this paper
• NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms.

  2000cited by this paper
• Bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by human NAD(P)H quinone oxidoreductase 2: a novel co-substrate-mediated antitumor prodrug therapy.

  2000cited by this paper
• Nitroreductase-mediated cell ablation is very rapid and mediated by a p53-independent apoptotic pathway

  1999cited by this paper
• Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954

  1998cited by this paper
• Gene-directed enzyme prodrug therapy: quantitative bystander cytotoxicity and DNA damage induced by CB1954 in cells expressing bacterial nitroreductase

  1998cited by this paper
• Development of a bicistronic vector driven by the human polypeptide chain elongation factor 1alpha promoter for creation of stable mammalian cell lines that express very high levels of recombinant proteins.

  1998cited by this paper
• Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene.

  1997cited by this paper
• Mustard prodrugs for activation by Escherichia coli nitroreductase in gene-directed enzyme prodrug therapy.

  1997cited by this paper
• Selective cell ablation in transgenic mice expressing E. coli nitroreductase

  1997cited by this paper
• The Bystander Effect of the Nitroreductase/CB 1954 Enzyme/Prodrug System Is Due to a Cell-Permeable Metabolite

  1997cited by this paper
• Hypoxia-selective antitumor agents. 14. Synthesis and hypoxic cell cytotoxicity of regioisomers of the hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide.

  1996cited by this paper
• Synthesis and evaluation of 4-substituted analogues of 5-[N,N-bis (2-chloroethyl)amino]-2-nitrobenzamide as bioreductively activated prodrugs using an Escherichia coli nitroreductase.

  1996cited by this paper
• Gene cloning, purification, and characterization of NfsB, a minor oxygen-insensitive nitroreductase from Escherichia coli, similar in biochemical properties to FRase I, the major flavin reductase in Vibrio fischeri.

  1996cited by this paper
• Bioactivation of mitomycin antibiotics by aerobic and hypoxic Chinese hamster ovary cells overexpressing DT-diaphorase.

  1996cited by this paper
• Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954.

  1995cited by this paper
• Reductive chemistry of the novel hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide.

  1995cited by this paper
• Physical characterisation of the Escherichia coli B gene encoding nitroreductase and its over-expression in Escherichia coli K12.

  1994cited by this paper
• The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--I. Purification and properties of a nitroreductase enzyme from Escherichia coli--a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT).

  1992cited by this paper
• Hypoxia-selective antitumor agents. 6. 4-(Alkylamino)nitroquinolines: a new class of hypoxia-selective cytotoxins.

  1992cited by this paper
• The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--II. A comparison of an Escherichia coli nitroreductase and Walker DT diaphorase.

  1992cited by this paper
• Bioactivation of CB 1954: reaction of the active 4-hydroxylamino derivative with thioesters to form the ultimate DNA-DNA interstrand crosslinking species.

  1991cited by this paper
• The differences in kinetics of rat and human DT diaphorase result in a differential sensitivity of derived cell lines to CB 1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide)

  1991cited by this paper
• New colorimetric cytotoxicity assay for anticancer-drug screening.

  1990cited by this paper
• A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells.

  1988cited by this paper
• Increased O6-alkylguanine alkyltransferase activity in Chinese hamster V79 cells following selection with chloroethylating agents.

  1988cited by this paper
• The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2).

  1988cited by this paper
• The metabolism of the anti-tumour agent 5-(1-aziridinyl)-2,4-dinitrobenzamide (CB 1954).

  1976cited by this paper
• Toxicity of the selective antitumor agent 5-aziridino-2,4-dinitrobenzamide in the rat.

  1970cited by this paper

• Cavity Filling-Based Enzyme Activatable Luminophores Leveraged In Vivo Bioimaging.

  2025cites this paper
• Nitrogen Mustard: a Promising Class of Anti-Cancer Chemotherapeutics – a Review

  2022cites this paper
• Interrogation of the Structure–Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications

  2022cites this paper
• Single- and Two-Electron Reduction of Nitroaromatic Compounds by Flavoenzymes: Mechanisms and Implications for Cytotoxicity

  2021cites this paper
• Use of an optimised enzyme/prodrug combination for Clostridia directed enzyme prodrug therapy induces a significant growth delay in necrotic tumours

  2021cites this paper
• E. coli nitroreductase NfsA is a reporter gene for non-invasive PET imaging in cancer gene therapy applications

  2020cites this paper
• Extracellular Vesicle–Mediated In Vitro Transcribed mRNA Delivery for Treatment of HER2+ Breast Cancer Xenografts in Mice by Prodrug CB1954 without General Toxicity

  2020cites this paper
• Therapeutic journery of nitrogen mustard as alkylating anticancer agents: Historic to future perspectives.

  2018cites this paper
• Prodrug strategy for cancer cell-specific targeting: A recent overview.

  2017cites this paper
• pH-Sensitive PEGylated liposomes for delivery of an acidic dinitrobenzamide mustard prodrug: Pathways of internalization, cellular trafficking and cytotoxicity to cancer cells.

  2017cites this paper
• Studies relating to the synthesis, enzymatic reduction and cytotoxicity of a series of nitroaromatic prodrugs.

  2016cites this paper
• M-Dinitroaromatic Moiety as a Fragment of Biologically Active Compounds

  2016cites this paper
• Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy.

  2016cites this paper
• Rational design of an AKR 1 C 3-resistant analog of PR-104 for enzyme-prodrug therapy

  2016cites this paper
• Unravelling the role of SNM1 in the DNA repair system of Trypanosoma brucei

  2015cites this paper
• A rapid response "Turn-On" fluorescent probe for nitroreductase detection and its application in hypoxic tumor cell imaging.

  2015cites this paper
• Evaluating and exploiting the function of a Leishmania major type I nitroreductase in the development of novel leishmanicidal prodrugs.

  2013cites this paper
• Evaluating Aziridinyl Nitrobenzamide Compounds as Leishmanicidal Prodrugs

  2013cites this paper
• Topoisomerase-II mediated biochemical mapping of centromeres and nitroreductase mediated drug metabolism in Trypanosomatids

  2012cites this paper
• Characterisation of enzyme prodrug gene therapy combinations in coated spheroids and vascular networks in vitro

  2012influential citation
• Directed Enzyme Prodrug Therapies

  2011cites this paper
• Discovery and Optimisation of Bacterial Nitroreductases for Use in Anti-Cancer Gene Therapy

  2011cites this paper
• Comparative Metabolism and Disposition of the Novel Anti-Tuberculosis Agent PA-824 in Mycobacteria, Mammals and Phagocytes

  2010cites this paper
• Trypanocidal Activity of Aziridinyl Nitrobenzamide Prodrugs (cid:1)

  2010cites this paper
• Trypanocidal Activity of Aziridinyl Nitrobenzamide Prodrugs

  2010influential citation
• Design of anticancer prodrugs for reductive activation

  2009cites this paper
• Bystander or No Bystander for Gene Directed Enzyme Prodrug Therapy

  2009cites this paper
• Organocatalytic aziridine synthesis using F+ salts.

  2009cites this paper
• Hepatic nitroreduction, toxicity and toxicokinetics of the anti-tumour prodrug CB 1954 in mouse and rat.

  2007cites this paper
• The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411NTR

  2007cites this paper
• Application of a microfluidic reactor for screening cancer prodrug activation using silica-immobilized nitrobenzene nitroreductase.

  2006cites this paper
• New enzyme for reductive cancer chemotherapy, YieF, and its improvement by directed evolution

  2006cites this paper
• Aerobic 2- and 4-nitroreduction of CB 1954 by human liver.

  2005cites this paper
• Advances in prodrug design.

  2005cites this paper
• Nitroarylmethylcarbamate prodrugs of doxorubicin for use with nitroreductase gene-directed enzyme prodrug therapy.

  2005cites this paper
• Latenciação e formas avançadas de transporte de fármacos

  2005cites this paper